Opinion|Videos|February 6, 2024
ASH 2023 Updates on Frontline Therapies in MCL
A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline MCL.
Advertisement
Episodes in this series
Advertisement
Related to this article
Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
A meta-analysis of 4 sonrotoclax cohorts showed consistent response activity and low tumor lysis rates in heavily pretreated mantle cell lymphoma.
The anti-CD19/CD20 CAR T-cell therapy will be studied in the phase 2 ABZT-121 trial after progression on commercial CAR T-cell therapy.
Rocbrutinib plus chemoimmunotherapy led to complete responses in patients with untreated B-cell lymphomas.
The FDA granted priority review to an sNDA for zanubrutinib plus rituximab in untreated mantle cell lymphoma.
Alembic's generic venetoclax, therapeutically equivalent to Venclexta, received final FDA approval for CLL/SLL and newly diagnosed AML.
Advertisement
Advertisement
Trending on OncLive
1
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
2
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
3
Dr Levy on Where Iza-Bren May Fit Following Osimertinib In EGFR-Mutated NSCLC
4
Dr Levy on How the EGFR-Targeted Therapy Landscape Has Evolved in NSCLC
5